Government-Owned Inventions; Availability for Licensing
The invention listed below is owned by an agency of the U.S. Government and is available for licensing as a biological material to achieve expeditious commercialization of resul...
The invention listed below is owned by an agency of the U.S. Government and is available for licensing as a biological material to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT:
Jeffrey Thruston at 301-594-5179 or
jeffrey.thruston@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
A VSV-EBOV-Based Vaccine Against COVID-19
Description of Technology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of for coronavirus disease 2019 (COVID-19). COVID-19 is characterized by fever, cough, difficulty breathing, loss of taste and smell, nausea, and sore throat. As of the fourth quarter 2020, COVID-19 is responsible for over 1.17 million deaths worldwide. As the pandemic continues to surge, the importance of a safe, affordable, and efficacious vaccine is of urgent importance. The present technology utilizes the well characterized vesicular stomatitis virus (VSV) encoding the Ebola virus (VSV-EBOV) to express additionally a codon-optimized SARS-CoV-2 spike protein. A single intranasal or intramuscular administration of the vaccine showed protective efficacy against COVID-19 in hamsters after 4 weeks. A single intramuscular injection showed protective efficacy against COVID-19 pneumonia in rhesus macaques within 10 days. The vaccine is inexpensive to replicate, elicits a high antigen-specific antibody titer within
( printed page 8214)
the host, and provides protective efficacy after a single dose.
This technology is available for licensing, as a biological material, for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
Single dose vaccine against COVID-19
Competitive Advantages
Utilizes the established and well characterized VSV-EBOV vector
Expresses high antigen titers within host cells
Single dose protective efficacy against COVID-19
Inexpensive and replicable
Development Stage
Prototype
In vivo/In vitro
Inventors:
Andrea Marzi (NIAID), Wakako Asada (NIAID).
Licensing Contact:
To license this technology, please contact Jeffrey Thruston at 301-594-5179 or
jeffrey.thruston@nih.gov,
and reference E-233-2017-0.
Dated: January 19, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.